TY - JOUR T1 - COVID-19 International Border Surveillance Cohort Study at Toronto’s Pearson Airport JF - medRxiv DO - 10.1101/2021.02.25.21252404 SP - 2021.02.25.21252404 AU - Vivek Goel AU - David Bulir AU - Eric De Propetis AU - Munaza Jamil AU - Laura Rosella AU - Dominik Mertz AU - Cheryl Regehr AU - Marek Smieja Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/01/2021.02.25.21252404.abstract N2 - Objectives The primary objective was to estimate the positivity rate of air travelers coming to Toronto, Canada in September and October, 2020, at arrival, day 7 and day 14. Secondary objectives were to estimate degree of risk based on country of origin; to assess knowledge and attitudes towards COVID-19 control measures; and subjective well-being during the quarantine period.Design Prospective cohort of arriving international travelers.Setting Toronto Pearson Airport Terminal 1, Toronto, Canada.Participants Passengers arriving on international flights. Inclusion criteria were those aged 18 or older who had a final destination within 100 km of the airport; spoke English or French; and provided consent. Excluded were those taking a connecting flight; who had no internet access; who exhibited symptoms of COVID-19 on arrival; or who were exempted from quarantine.Main outcome measures Positive for SARS-CoV-2 virus on RT-PCR with self-administered nasal-oral swab, and general well-being using the WHO-5 index.Results Of 16,361 passengers enrolled, 248 (1·5%, 95% CI 1.3%,1.5%) tested positive. Of these, 167 (67%) were identified on arrival, 67 (27%) on day 7, and 14 (6%) on day 14. The positivity rate increased from 1% in September to 2% in October. Average well-being score declined from 19.8 (out of a maximum of 25) to 15.5 between arrival and day 7 (p<0.001).Conclusions A single arrival test will pick up two-thirds of individuals who will become positive, with most of the rest detected on the second test at day 7. These results support strategies identified through mathematical models that a reduced quarantine combined with testing can be as effective as a 14 day quarantine.Strengths and limitations of this studyDecisions regarding border restrictions have been based on trial and error and mathematical models with limited empirical data to support such decision-making.This study assessed the prevalence of SARS-CoV-2 in a cohort of international travellers at arrival, day 7 and 14 of quarantine.It is limited to one airport and there is the potential from bias due to non-participation and loss to follow-up.Self-collected nasal-oral swabs were used which facilitated participation but may have reduced sensitivity.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no personal financial support from any organisation for the submitted work. MS and DB are on the Board of Directors of McMaster Health Labs. DB is the developer of McMaster Molecular Medium.Funding StatementMcMaster Health Labs (MHL) is a not-for-profit corporation created by McMaster University and Research St. Joseph's to conduct COVID-19 related lab research. The contracts for funding with Air Canada and the Greater Toronto Airport Authority were with MHL. The funders also provided in-kind support for recruitment of participants and the study site at the airport. The Canadian Institutes for Health Research awarded a peer-reviewed grant for conduct of the study. The funders did not have any direction in the study design, execution, data analysis, or preparation of the manuscripts.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Advara Research Ethics BoardAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDeidentified participant data will be made available with publication through an open data repository. ER -